Key Information - The discloser is Avadel Pharmaceuticals plc, which is the offeree in relation to its relevant securities [2][4] - The position was held as of November 4, 2025 [2] - There are no interests or short positions disclosed for the relevant securities [4] Interests and Short Positions - No relevant securities owned or controlled by the discloser [4] - No cash-settled or stock-settled derivatives reported [4] - Total interests and short positions are NIL [4] Interests of Persons Acting in Concert - Total interests held by directors of Avadel Pharmaceuticals plc amount to 794,959 ordinary shares, representing 0.81% of the total issued ordinary share capital [6] - The total number of underlying stock options and other rights held by these directors is 4,347,557 [6] Other Information - No indemnity or other dealing arrangements were reported [9] - No agreements or arrangements relating to options or derivatives were disclosed [9] - A Supplemental Form 8 is not attached [10]

Key Information - The disclosure is made by Mural Oncology plc, which is the offeree in relation to its relevant securities [2][5] - The position held date is April 29, 2025, which is the latest practicable date prior to the disclosure [2] - There are no interests or short positions disclosed for Mural Oncology plc [5] Interests and Short Positions - The table indicates that there are no relevant securities owned or controlled, cash-settled derivatives, or stock-settled derivatives by the discloser [5] - Total interests and short positions are reported as NIL [5] Interests of Directors - Caroline Loew holds 43,622 ordinary shares, representing 0.25% of the total issued share capital, with a total of 865,908 underlying stock options and other rights [7] - Other directors have varying numbers of underlying shares, with a total of 967,026 ordinary shares accounted for among them [7] Other Information - There are no indemnity or option arrangements or agreements related to relevant securities that may influence dealings [8] - No supplemental forms are attached to this disclosure [11]